Table 5.
Parameter | Disease-free survival | Overall survival | ||
---|---|---|---|---|
| ||||
Median survival (95% CI) months | P-value | Median survival (95% CI) months | P-value | |
Nuclear beclin-1 (E)* | 0.247 | 0.750 | ||
Negative | 168 (159-177) | 181 (177-184) | ||
Positive | 171 (164-179) | 176 (172-181) | ||
Cytoplasmic beclin-1 (E)* | 0.319 | n/a | ||
Negative | 174 (167-181) | n/a | ||
Positive | 161 (150-172) | n/a | ||
Nuclear beclin-1 (S) | 0.013 | 0.044 | ||
Negative | 169 (162-176) | 177 (172-181) | ||
Positive | 74 (56-91) | 84 (69-98) | ||
Cytoplasmic beclin-1 (S) | 0.748 | 0.107 | ||
Negative | 167 (160-174) | 177 (172-181) | ||
Positive | 86 (75-97) | 86 (76-97) | ||
LC3A (E)* | n/a | n/a | ||
Negative | n/a | n/a | ||
Positive | n/a | n/a | ||
LC3A (S) | <0.001 | <0.001 | ||
Negative | 174 (168-180) | 181 (179-184) | ||
Positive | 121 (106-136) | 130 (116-144) | ||
LC3B (E)* | 0.515 | 0.173 | ||
Negative | 146 (132-160) | 154 (146-163) | ||
Positive | 172 (165-179) | 181 (179-184) | ||
LC3B (S) | 0.119 | <0.001 | ||
Negative | 170 (162-177) | 181 (178-184) | ||
Positive | 155 (140-170) | 158 (144-172) | ||
p62 (E)* | n/a | n/a | ||
Negative | n/a | n/a | ||
Positive | n/a | n/a | ||
p62 (S) | 0.012 | 0.004 | ||
Negative | 172 (165-179) | 180 (176-183) | ||
Positive | 120 (107-132) | 129 (120-139) |
14 cases without an epithelial component were excluded.
E, epithelial component. S, stromal component.